Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics (AXSM) and Viking Therapeutics (VKTX) are compared as potential healthcare stock investments. Axsome, with products like Auvelity and Sunosi, reported $638.5M revenue in FY 2025, up 65.5%, but a net loss of $183.2M. Viking, in clinical trials, has no revenue but focuses on obesity treatments. Axsome has significant debt, while Viking has no debt but high research costs. Both face risks, with Axsome's reliance on few products and Viking's clinical trial uncertainties.
How this was made
The 30-second read
Why it matters
The article offers a side‑by‑side assessment but no new catalyst; it serves more as a portfolio‑allocation opinion.
Market read
Low trading relevance; primarily an opinion piece with modest new data.
What to watch
Potential impact of upcoming FDA decisions on Axsome's new Alzheimer’s indication and Viking's Phase 3 data timeline.
Background
The piece compares two Nasdaq‑listed biotech firms, providing FY 2025 financial snapshots and strategic commentary.
Ticker impact
Article details Axsome's FY 2025 revenue, losses, debt and a new settlement granting generic licenses for Sunosi, providing fresh financial and operational data.
Potential short‑term downside pressure unless guidance improves.
Numbers are disclosed for the first time in this piece, but they are not surprising; they reinforce existing risk concerns.
Article outlines Viking's FY 2025 zero revenue, large net loss, debt‑free balance sheet and progress on obesity drug VK2735, presenting new company‑specific financial metrics.
Volatile trading likely; upside if Phase 3 data are positive.
First‑time disclosure of detailed FY 2025 figures adds modest new information but does not constitute a material catalyst.
Market effects
Both companies illustrate the split between commercial‑stage biotech and clinical‑stage obesity players, highlighting divergent risk‑return dynamics in healthcare.
No specific regional effect; both are US‑listed Nasdaq issuers.
Limited; the article is a niche comparison rather than a market‑wide driver.
Counterpoint
Investors might favor Axsome despite debt if they value near‑term cash flow versus Viking's speculative upside.
Key entities
- companyAxsome Therapeutics
Commercial‑stage CNS drug developer.
- companyViking Therapeutics
Clinical‑stage obesity drug developer.
